Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

54.22 +0.22 (+0.41%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 15 Years
Via Benzinga
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - A Strong Candidate for Affordable Growth Investors
HALOZYME THERAPEUTICS (NASDAQ:HALO) offers strong growth, solid profitability, and reasonable valuation, making it a standout in affordable growth investing. 
Via Chartmill
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) – A Biotech Stock With Strong Fundamentals and Attractive Valuation
HALOZYME THERAPEUTICS (NASDAQ:HALO) offers a rare mix of strong growth, profitability, and financial health at an attractive valuation, making it a standout in the biotech sector. 
Via Chartmill
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) – A Strong Growth Stock with Technical Breakout Potential
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) shows strong growth fundamentals and a potential technical breakout, making it a stock to watch in the biotech sector. 
Via Chartmill
Here's How Much $100 Invested In Halozyme Therapeutics 15 Years Ago Would Be Worth Today
Via Benzinga
What's Driving the Market Sentiment Around Halozyme Therapeutics?
Via Benzinga
Price Over Earnings Overview: Halozyme Therapeutics
Via Benzinga
Earnings Scheduled For May 6, 2025
Via Benzinga
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - A Strong Candidate for Affordable Growth Investors
HALOZYME THERAPEUTICS (NASDAQ:HALO) offers strong growth, solid profitability, and an attractive valuation, making it a standout in the biotech sector for investors seeking affordable growth... 
Via Chartmill
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years
Via Benzinga
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) – A Biotech Stock With Strong Fundamentals and Attractive Valuation
HALOZYME THERAPEUTICS (NASDAQ:HALO) offers strong profitability, financial health, and growth at an attractive valuation, making it a potential value opportunity in biotech. 
Via Chartmill
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
The Benzinga Stock Whisper Index highlights five stocks seeing increased interest from readers during the week and a look at what's drivin the interest. 
Via Benzinga
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - A Strong Candidate for Affordable Growth Investors
HALOZYME THERAPEUTICS (NASDAQ:HALO) offers strong growth, solid profitability, and an attractive valuation, making it a standout in the biotech sector for investors seeking affordable growth... 
Via Chartmill
Evolv Technologies, Quantum Computing, ACADIA Pharmaceuticals And Other Big Stocks Moving Higher On Friday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Crude Oil Gains 3%; US Inflation Eases In April
Via Benzinga
Topics Economy
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
There are notable gap-ups and gap-downs in today's session.
Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News
It's biggest product will be up for price negotiations under the Inflation Reduction Act much sooner than expected. 
Via Investor's Business Daily
Topics Economy Government
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) – An Undervalued Biotech Stock Worth Watching
HALOZYME THERAPEUTICS (NASDAQ:HALO) is an undervalued biotech stock with strong profitability, financial health, and growth potential, making it a compelling pick for value investors. 
Via Chartmill
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 15 Years
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Insights into Halozyme Therapeutics's Upcoming Earnings
Via Benzinga
While growth is established for HALOZYME THERAPEUTICS INC (NASDAQ:HALO), the stock's valuation remains reasonable.
HALOZYME THERAPEUTICS INC was identified as an affordable growth stock. NASDAQ:HALO is showing great growth, but also scores well on profitability. At the same time it seems to be priced reasonably. 
Via Chartmill
Deep Dive Into Halozyme Therapeutics Stock: Analyst Perspectives (5 Ratings)
Via Benzinga
Halozyme Sues Merck Over Subcutaneous Keytruda Formulation, Seeks Injunctive Relief
Halozyme said that it believes the subcutaneous formulation of Merck's cancer medicine Keytruda infringes multiple patents that Halozyme filed beginning in 2011 to protect its groundbreaking MDASE... 
Via Stocktwits
Topics Intellectual Property Lawsuit
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years
Via Benzinga
HALOZYME THERAPEUTICS INC (NASDAQ:HALO), a strong growth stock, setting up for a breakout.
Based on a technical and fundamental analysis of NASDAQ:HALO we conclude: HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—A High-Growth Stock Gearing Up for Its Next Upward Move. 
Via Chartmill
FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting
FDA approves Argenx's Vyvgart Hytrulo prefilled syringe for self-injection in gMG and CIDP, offering flexible dosing and expanding treatment options. 
Via Benzinga
Peering Into Halozyme Therapeutics's Recent Short Interest
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.